Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2016 May 9.

Published in final edited form as: Neuropathology. 2012 Sep 19;33(2):162–174. doi: 10.1111/j.1440-1789.2012.01344.x

Fig. 2 — Effects of cilengitide on tube formation. HUVECs co-cultured with fibroblasts and VEGF (10 ng/mL) without cilengitide (A) or with cilengitide (0.1, 0.5, 1.0 µM) (B–D) or suramin (50 µM) (E) for ten days. The length of tube-like structures was measured quantitatively using an image analyzer. The tube length was significantly shortened with cilengitide treatment in a concentration-dependent manner (*P = 0.0062, **P = 0.0089). (mean ± SE, n = 6)

Fig. 2 — Effects of cilengitide on tube formation. HUVECs co-cultured with fibroblasts and VEGF (10 ng/mL) without cilengitide (A) or with cilengitide (0.1, 0.5, 1.0 µM) (B–D) or suramin (50 µM) (E) for ten days. The length of tube-like structures was measured quantitatively using an image analyzer. The tube length was significantly shortened with cilengitide treatment in a concentration-dependent manner (*P = 0.0062, **P = 0.0089). (mean ± SE, n = 6)